PRECIGEN, INC. Long-Term Debt, Maturity, Year Three
PRECIGEN, INC. (PGEN) had Long-Term Debt, Maturity, Year Three of $12.50 million as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2026-03-25
- 2025-12-31: Long-Term Debt, Maturity, Year Three $12.50M.
- 2025-09-30: Long-Term Debt, Maturity, Year Three $12.50M.
- 2022-12-31: Long-Term Debt, Maturity, Year Three $0.00.
- 2022-03-31: Long-Term Debt, Maturity, Year Three $395.00K.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2025-12-31 | $12.50M 10-K · filed 2026-03-25 |
| 2025-09-30 | $12.50M 10-Q · filed 2025-11-13 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-06 |
| 2022-03-31 | $395.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $379.00K 10-K · filed 2022-03-01 |
| 2021-09-30 | $378.00K 10-Q · filed 2021-11-08 |
| 2021-06-30 | $376.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $375.00K 10-Q · filed 2021-05-10 |
| 2020-12-31 | $200.36M 10-K · filed 2021-03-01 |
| 2020-09-30 | $200.36M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $200.36M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $343.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $341.00K 10-K · filed 2020-03-02 |
| 2019-09-30 | $25.33M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $25.33M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $25.45M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $25.41M 10-K · filed 2019-03-01 |
| 2018-09-30 | $30.46M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $382.00K 10-Q · filed 2018-08-13 |
| 2018-03-31 | $382.00K 10-Q/A · filed 2018-08-13 |
| 2017-12-31 | $372.00K 10-K · filed 2018-03-01 |
| 2017-09-30 | $400.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $397.00K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $395.00K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $365.00K 10-K · filed 2017-03-01 |
| 2016-09-30 | $549.00K 10-Q · filed 2016-11-09 |
| 2016-06-30 | $529.00K 10-Q · filed 2016-08-09 |
| 2016-03-31 | $527.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $526.00K 10-K · filed 2016-02-29 |
| 2015-09-30 | $382.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $365.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $364.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $363.00K 10-K · filed 2015-03-02 |
| 2014-09-30 | $1.07M 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |